SIGN UP
LOG IN
I
IMAB
I-Mab
0.87
-0.07-7.18%After Hours: 0.8719 -0.00 -0.07%16:09 05/01 EDT
OPEN/PREV CLOSE0.8800/0.9400
TODAY RANGE0.8712-0.9328
VOL28.75K
MARKET CAP71.11M
52 WEEK RANGE0.5950-2.000
AVG VOL (3M)226.62K
% TURNOVER0.04%
TURNOVER--
P/E (TTM)-3.1866
% RANGE6.55%
EPS(TTM)-0.2738
P/E(FORWARD)-3.2315
P/B0.3535
BVPS2.468
DIVIDEND--
P/S300.86
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP50.41M
SHARES OUTSTANDING81.50M
NEXT EARNINGS08/26-09/01
FREE FLOAT57.78M
LOT SIZE1
EX-DIV DATE--
News
Press Releases
Financial Reports
Profile
Benzinga·04/14 17:05
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga·04/07 12:08
12 Health Care Stocks Moving In Monday's Pre-Market Session
TipRanks·04/05 03:50
I-Mab’s Transformative Year: Financial and Strategic Highlights
TipRanks·04/04 21:31
I-Mab Positions for Growth with U.S. Focus and Innovative Cancer Treatments
Benzinga·04/04 21:05
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga·04/04 12:55
ADT To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Friday
Dow Jones·04/04 11:49
I-Mab Price Target Maintained With a $4.00/Share by Needham
Dow Jones·04/04 11:47
I-Mab Is Maintained at Buy by HC Wainwright & Co.
Dow Jones·04/04 11:47
I-Mab Price Target Cut to $7.00/Share From $8.00 by HC Wainwright & Co.
Benzinga·04/04 11:39
Needham Reiterates Buy on I-MAB, Maintains $4 Price Target
Benzinga·04/04 11:37
HC Wainwright & Co. Maintains Buy on I-MAB, Lowers Price Target to $7
TipRanks·04/04 10:26
Promising Pipeline and Strong Financial Position Drive Buy Rating for I-Mab
Same Industry
Name/Symbol
Change%
Price
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.